Pontifax Invests in Israeli Protein Expression Company - Protalix Biotherapeutics Ltd.
Protalix has developed and patented a unique plant cell culture platform and bioreactor system which provides an efficient, easily scaleable and cost-effective system for the expression of human therapeutic proteins. The company's lead program is the development of Glucocerebrosidase, as a proprietary enzyme replacement therapy for the treatment of Gaucher Disease, a genetic metabolic disorder. Gaucher disease is the most prevalent lysosomal storage disorder. The drug is slated to begin clinical trials during 2005. Additional proprietary protein programs are ongoing.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.